Comerica Securities Inc. boosted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 8.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,394 shares of the biopharmaceutical company’s stock after acquiring an additional 196 shares during the quarter. Comerica Securities Inc.’s holdings in Alexion Pharmaceuticals were worth $291,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. raised its position in Alexion Pharmaceuticals by 2,689.8% during the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock worth $2,258,467,000 after acquiring an additional 17,960,356 shares in the last quarter. Vanguard Group Inc. raised its position in Alexion Pharmaceuticals by 3.1% during the first quarter. Vanguard Group Inc. now owns 14,467,456 shares of the biopharmaceutical company’s stock worth $1,754,034,000 after acquiring an additional 433,293 shares in the last quarter. State Street Corp raised its position in Alexion Pharmaceuticals by 6.8% during the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock worth $1,369,846,000 after acquiring an additional 718,756 shares in the last quarter. Ameriprise Financial Inc. raised its position in Alexion Pharmaceuticals by 0.4% during the second quarter. Ameriprise Financial Inc. now owns 6,175,296 shares of the biopharmaceutical company’s stock worth $751,363,000 after acquiring an additional 25,724 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Alexion Pharmaceuticals by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 3,349,821 shares of the biopharmaceutical company’s stock worth $407,573,000 after acquiring an additional 64,800 shares in the last quarter. 94.26% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have issued reports on ALXN. Jefferies Group LLC set a $120.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, June 8th. UBS AG reaffirmed a “buy” rating and set a $140.00 price target (down from $143.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 31st. Stifel Nicolaus reaffirmed a “buy” rating and set a $157.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $180.00 price target (up from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday. Finally, J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, June 14th. Five equities research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and three have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $157.13.

Alexion Pharmaceuticals, Inc. (ALXN) opened at 146.69 on Friday. The firm has a market capitalization of $32.74 billion, a P/E ratio of 63.61 and a beta of 1.40. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $149.34. The company has a 50 day moving average of $138.83 and a 200 day moving average of $124.75.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.48. The company had revenue of $912.00 million for the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same period in the previous year, the business posted $1.13 EPS. On average, equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.62 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Comerica Securities Inc. Has $291,000 Holdings in Alexion Pharmaceuticals, Inc. (ALXN)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/17/comerica-securities-inc-has-291000-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

In related news, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now directly owns 5,480 shares in the company, valued at approximately $799,038.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Julie O’neill sold 4,375 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total value of $636,300.00. Following the completion of the sale, the executive vice president now owns 26,092 shares in the company, valued at $3,794,820.48. The disclosure for this sale can be found here. Insiders have sold a total of 17,070 shares of company stock worth $2,416,869 over the last quarter. Company insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.